GO:1904482 cellular response to tetrahydrofolate: One-Carbon Metabolism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1904482 describes how a single cell changes its state, activity, enzyme production or gene expression after exposure to tetrahydrofolate (THF), the fully reduced folate cofactor.
• Tetrahydrofolate is the central carrier of one-carbon units used for nucleotide synthesis, methionine recycling and glycine production, so the response touches DNA replication, epigenetics and redox balance.
• Clinically, the term is most relevant to antifolate chemotherapy (methotrexate, FOLFOX, FOLFIRINOX), where rescue with folinic acid (5-formyl-THF) directly modulates the cellular THF pool.
• Cancer cells that survive antifolate exposure reprogram one-carbon flux, senescence and immune visibility, making this response a therapeutic target.
• Cerebral folate deficiency shows that impaired THF availability in the central nervous system causes neurological disease, linking the term to neurobiology.
• CRISPR knockout, point-mutation, knock-in and overexpression models are the standard tools to test which genes causally mediate the cellular response to tetrahydrofolate.
Description
GO:1904482, cellular response to tetrahydrofolate, is a biological process term that captures any change in a cell's state or activity after it is stimulated by tetrahydrofolate (THF), the fully reduced, one-carbon-carrying form of folate. The response can involve altered movement, secretion, enzyme production or gene expression, and it is therefore a broad, integrative term rather than a single pathway. Because THF sits at the crossroads of nucleotide biosynthesis, amino acid interconversion and methylation, the response is central to how cells cope with proliferative demand and metabolic stress. For researchers, GO:1904482 is a useful annotation anchor when studying antifolate drugs, one-carbon metabolism and folate-dependent disease. Methotrexate and 5-fluorouracil-based regimens such as FOLFOX and FOLFIRINOX perturb intracellular folate pools, and the cellular response to tetrahydrofolate determines whether cells arrest, die or adapt. In pancreatic cancer, transcriptome-based classification and organoid models have been used to predict FOLFIRINOX response, directly implicating folate-dependent programs in clinical outcome. This article summarizes the QuickGO definition, the mechanistic stages of the response, the genes and proteins involved, disease links and the CRISPR and multi-omics methods used to study it. All statements are tied to verified PubMed literature so that the content can be used for both search retrieval and generative-AI grounding-.
cellular response to tetrahydrofolate At A Glance
| GO ID | GO:1904482 |
|---|---|
| GO term | cellular response to tetrahydrofolate |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Definition | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a tetrahydrofolate stimulus. |
| Major function | Couples tetrahydrofolate availability to nucleotide synthesis, one-carbon flux, methylation and stress adaptation |
| Stimulus | Tetrahydrofolate (THF), the fully reduced folate cofactor |
| Related chemistry | One-carbon transfer, glycine synthesis, methionine recycling |
| Disease relevance | Antifolate chemotherapy response, cerebral folate deficiency, pancreatic and hepatocellular cancer |
What Is GO:1904482?
In plain terms, GO:1904482 means: a cell senses tetrahydrofolate and changes what it does. Formally, it is any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a tetrahydrofolate stimulus. The term is a biological_process in the Gene Ontology and has no listed synonyms. It is downstream of tetrahydrofolate availability and is therefore tightly coupled to one-carbon metabolism, nucleotide synthesis and methylation reactions.
Why Is cellular response to tetrahydrofolate Important in Cell Biology?
The cellular response to tetrahydrofolate is important because it determines how a cell allocates one-carbon units to DNA synthesis, amino acid metabolism and methylation, and because it is the mechanistic interface of antifolate chemotherapy. When THF availability changes, cells must rewire gene expression, enzyme production and proliferation, and failure to do so contributes to drug resistance, neurodevelopmental disease and metabolic dysfunction.
• Tetrahydrofolate is the central one-carbon carrier for purine and thymidylate synthesis, so the response directly controls proliferation.
• It shapes the cellular response to methotrexate and other antifolates, and folinic acid rescue is a clinical manipulation of this response.
• In hepatocellular carcinoma, FOLFOX-HAIC therapy remodels the tumor microenvironment and tertiary lymphoid structures, linking folate stress to anti-tumor immunity.
• In pancreatic ductal adenocarcinoma, FOLFIRINOX response can be predicted from transcriptome-based classification, implicating folate-dependent programs.
• Senescence reprogramming after FOLFIRINOX chemotherapy involves exosomal cargo and anti-tumor immunity, connecting the response to aging biology.
• Patient-derived 3D organoid models preserve folate-dependent phenotypes and bridge preclinical and clinical insights.
• Epithelial-mesenchymal plasticity in pancreatic cancer is a therapeutic target that intersects with metabolic stress responses.
• Cerebral folate deficiency demonstrates that impaired THF handling causes neurological disease.
• Mitochondrial one-carbon metabolism is required for TGF-beta-induced glycine synthesis and fibrotic responses, expanding the term beyond oncology.
• The response is a tractable CRISPR target space for knockout, point-mutation, knock-in and overexpression screens.
What Happens During cellular response to tetrahydrofolate?
Sensing tetrahydrofolate availability
In simple terms: The cell first notices how much tetrahydrofolate it has.
The response begins when intracellular tetrahydrofolate levels change, either through uptake, polyglutamation or antifolate inhibition. Because THF is the fully reduced folate cofactor, its availability sets the capacity for one-carbon transfer reactions that feed nucleotide and amino acid synthesis. In cancer cells treated with FOLFOX or FOLFIRINOX, this sensing step is perturbed and triggers downstream transcriptional and metabolic remodeling.
One-carbon flux and nucleotide synthesis
In simple terms: The cell uses tetrahydrofolate to build the letters of DNA.
Once THF is available, one-carbon units are channeled into purine and thymidylate biosynthesis. Mitochondrial one-carbon metabolism is required for TGF-beta-induced glycine synthesis and fibrotic responses, showing that the flux is not limited to the nucleus. When this flux is blocked by antifolates, cells arrest or die, and surviving cells may reprogram senescence and immune visibility.
Methionine cycle and methylation
In simple terms: Tetrahydrofolate helps recycle methionine, which the cell uses to tag DNA and proteins.
THF participates in the methionine cycle by supporting homocysteine remethylation, which regenerates S-adenosylmethionine for methylation reactions. This links the cellular response to tetrahydrofolate with epigenetic regulation and gene expression changes that are part of the GO:1904482 definition.
Transcriptional and secretory remodeling
In simple terms: The cell changes which genes it turns on and what it releases.
The GO definition explicitly includes changes in gene expression and secretion. Transcriptome-based classification of pancreatic cancer predicts FOLFIRINOX response, indicating that folate stress induces measurable transcriptional programs. Exosomal cargo such as SenExo-cCCT2 reprograms senescence and anti-tumor immunity after FOLFIRINOX, illustrating a secretory arm of the response.
Microenvironment and immune consequences
In simple terms: What the cell does next can change how the immune system sees the tumor.
In hepatocellular carcinoma, FOLFOX-HAIC therapy enhances tertiary lymphoid structure formation and shapes an anti-tumor microenvironment, showing that the cellular response to tetrahydrofolate extends to immune cell recruitment. Epithelial-mesenchymal plasticity in pancreatic cancer is another therapeutic target that intersects with this stress response.
Key Genes Involved in GO:1904482 cellular response to tetrahydrofolate
The following genes and proteins are experimentally linked to tetrahydrofolate handling, one-carbon metabolism and the cellular response to antifolate stimuli.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MTHFR | Reduces 5,10-methylene-THF to 5-methyl-THF | Central to methionine cycle and methylation |
| MTR | Methionine synthase, uses 5-methyl-THF | Links THF to homocysteine remethylation |
| SHMT1 | Serine hydroxymethyltransferase, cytoplasmic | Generates one-carbon units for THF pool |
| SHMT2 | Serine hydroxymethyltransferase, mitochondrial | Required for TGF-beta-induced glycine synthesis |
| MTHFD2 | Mitochondrial one-carbon metabolism | Supports glycine synthesis and fibrotic responses |
| TYMS | Thymidylate synthase, uses 5,10-methylene-THF | Direct antifolate target |
| DHFR | Dihydrofolate reductase, regenerates THF | Methotrexate target and rescue node |
| GART | Purine biosynthesis, folate-dependent | Connects THF to nucleotide synthesis |
| ATIC | Purine biosynthesis, folate-dependent | Downstream of one-carbon flux |
| SLC19A1 | Reduced folate carrier | Controls THF uptake and response magnitude |
| FOLR1 | Folate receptor alpha | Mediates folate transport in brain and tumors |
| CCT2 | Chaperonin, exosomal cargo | SenExo-cCCT2 reprograms senescence after FOLFIRINOX |
| TGFB1 | Cytokine driving fibrosis | Induces glycine synthesis via one-carbon metabolism |
| CD8A | T cell marker | Tertiary lymphoid structures and anti-tumor immunity |
| EPCAM | Epithelial marker | Epithelial-mesenchymal plasticity in pancreatic cancer |
| VIM | Mesenchymal marker | Plasticity and therapy response |
| MKI67 | Proliferation marker | Readout of folate-dependent proliferation |
How Is cellular response to tetrahydrofolate Regulated?
The cellular response to tetrahydrofolate is regulated at multiple levels. Substrate availability is controlled by folate transporters such as SLC19A1 and FOLR1, and by polyglutamation enzymes that retain THF intracellularly. Enzyme abundance and activity of DHFR, TYMS, MTHFR and SHMT isoforms set the flux capacity, and antifolates such as methotrexate directly inhibit DHFR and thereby reshape the response. Transcriptional programs downstream of TGF-beta and other stress signals can induce mitochondrial one-carbon enzymes, as shown for glycine synthesis in fibrotic responses. In tumors, therapy-induced stress can trigger senescence and exosomal signaling that further modifies the response. Together, these layers determine whether a cell adapts, arrests or dies after a tetrahydrofolate stimulus.
cellular response to tetrahydrofolate and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DHFR | Methotrexate toxicity and rescue | Knockout and point-mutation cell lines with folinic acid rescue |
| MTHFD2 | TGF-beta-induced fibrosis | Knockout in fibroblast or epithelial cells with glycine readout |
| CCT2 | Senescence and anti-tumor immunity after FOLFIRINOX | Overexpression and knockout with exosome profiling |
| SLC19A1 | Cerebral folate deficiency and transport defects | Knock-in of patient variants in neuronal models |
| EPCAM/VIM | Epithelial-mesenchymal plasticity in pancreatic cancer | Organoid models with FOLFIRINOX exposure |
Antifolate chemotherapy response in cancer
Methotrexate, FOLFOX and FOLFIRINOX all perturb tetrahydrofolate pools, and the cellular response to tetrahydrofolate determines toxicity and efficacy. Folinic acid and glucarpidase are used to manage methotrexate toxicity by manipulating folate rescue, directly illustrating the clinical importance of this GO term. In hepatocellular carcinoma, FOLFOX-HAIC therapy enhances tertiary lymphoid structures and shapes an anti-tumor microenvironment, linking the response to immune remodeling. In pancreatic cancer, transcriptome-based classification predicts FOLFIRINOX response, and exosomal cargo such as SenExo-cCCT2 reprograms senescence and anti-tumor immunity after treatment.
Cerebral folate deficiency and neurobiology
Cerebral folate deficiency is a neurological disorder in which folate availability in the central nervous system is insufficient, causing developmental and cognitive symptoms. This condition demonstrates that the cellular response to tetrahydrofolate is essential for normal brain function and that transport and metabolism defects can produce disease.
Fibrosis and TGF-beta signaling
Mitochondrial one-carbon metabolism is required for TGF-beta-induced glycine synthesis and fibrotic responses, showing that the cellular response to tetrahydrofolate extends to extracellular matrix remodeling and fibrogenesis. This broadens the disease relevance of GO:1904482 beyond oncology and neurobiology.
Pancreatic cancer plasticity and therapy resistance
Epithelial-mesenchymal cellular plasticity is a therapeutic target in pancreatic cancer, and it intersects with metabolic stress responses induced by FOLFIRINOX. Patient-derived organoid models preserve these phenotypes and allow preclinical testing of combination strategies.
From cellular response to tetrahydrofolate-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is DHFR required for the cellular response to tetrahydrofolate? | CRISPR knockout in cancer cell lines |
| Does a patient variant in SLC19A1 alter folate uptake? | Point-mutation knock-in in neuronal or epithelial cells |
| Can a tagged one-carbon enzyme report flux in live cells? | Tagged knock-in with fluorescent or proximity tag |
| Does overexpression of CCT2 reprogram senescence? | Overexpression and exosome profiling |
| Which genes mediate FOLFIRINOX response? | CRISPR library screening in pancreatic organoids |
| How does epithelial-mesenchymal plasticity respond to folate stress? | Organoid and 3D models with lineage markers |
How to Study the cellular response to tetrahydrofolate Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Gene expression changes after THF stimulus | Transcriptome-based response classification |
| Metabolomics | One-carbon metabolites and glycine | Flux analysis in fibrosis models |
| Isotope tracing | One-carbon unit flow | Quantifying THF-dependent synthesis |
| Organoid culture | 3D growth and drug response | Pancreatic cancer preclinical models |
| Exosome profiling | Secreted cargo and senescence | FOLFIRINOX response and immunity |
| Imaging | Tertiary lymphoid structures | HCC microenvironment after FOLFOX-HAIC |
| CRISPR screening | Causal gene identification | Folate response and resistance |
| Immune profiling | T cell infiltration and activation | Anti-tumor immunity after therapy |
Transcriptomics and response classification
RNA-seq and transcriptome-based classification are used to define the gene expression arm of the cellular response to tetrahydrofolate. In pancreatic cancer, transcriptome-based classification predicts FOLFIRINOX response in real-world cohorts, showing that the response has a measurable transcriptional signature.
Metabolomics and one-carbon flux
Metabolomics and isotope tracing measure one-carbon flux, glycine synthesis and methionine cycle activity. Mitochondrial one-carbon metabolism is required for TGF-beta-induced glycine synthesis, and such experiments directly quantify the metabolic output of the response.
Organoid and 3D culture
Patient-derived 3D organoid models from conditionally reprogrammed cells bridge preclinical and clinical insights in pancreatic cancer, and they preserve folate-dependent phenotypes for functional testing. These models are especially useful when combined with antifolate exposure.
Imaging and immune profiling
Imaging and immune profiling reveal microenvironment consequences of the response. In hepatocellular carcinoma, FOLFOX-HAIC therapy enhances tertiary lymphoid structure formation, which can be quantified by imaging and immune cell markers. Exosomal cargo analysis after FOLFIRINOX links secretion to senescence and immunity.
How CRISPR Can Be Used to Study GO:1904482 cellular response to tetrahydrofolate
Knockout
CRISPR knockout is used to remove candidate genes such as DHFR, MTHFD2 or SLC19A1 and test whether the cellular response to tetrahydrofolate is lost. Knockout of mitochondrial one-carbon enzymes blocks TGF-beta-induced glycine synthesis, providing a direct causal test. Knockout screens in pancreatic organoids can identify genes required for FOLFIRINOX response.
Point Mutation
Point-mutation models introduce specific amino acid changes to test catalytic residues or patient variants. For example, variants in folate transporters can be modeled to determine whether they impair the cellular response to tetrahydrofolate. Such models are essential when the question is about enzyme activity rather than presence or absence.
Knock-in
Knock-in is used to add tags, reporters or patient alleles at endogenous loci. A tagged one-carbon enzyme can report flux in live cells, and a knock-in of a disease variant can recreate the altered response seen in cerebral folate deficiency. This approach preserves endogenous regulation, which is important for a stimulus-response term like GO:1904482.
Overexpression
Overexpression tests sufficiency: does increasing a gene product enhance or reprogram the response? Overexpression of exosomal cargo such as CCT2 reprograms senescence and anti-tumor immunity after FOLFIRINOX, showing that gain-of-function models can reveal new mechanisms. Overexpression is also used to test whether a transporter or enzyme can rescue antifolate toxicity.
How EDITGENE Supports cellular response to tetrahydrofolate Research
Researchers studying cellular response to tetrahydrofolate-related genes often need to determine whether a candidate gene is causally involved in sensing, flux or downstream remodeling. EDITGENE provides the CRISPR cell models and screening services needed to move from correlation to causation in this pathway.
Contact EDITGENE today to design your custom CRISPR model for cellular response to tetrahydrofolate research.
Frequently Asked Questions About cellular response to tetrahydrofolate
What is GO:1904482 cellular response to tetrahydrofolate?
GO:1904482 is a Gene Ontology biological process term describing any change in a cell's state or activity, including movement, secretion, enzyme production or gene expression, after a tetrahydrofolate stimulus.
What genes are involved in the cellular response to tetrahydrofolate?
Key genes include DHFR, TYMS, MTHFR, MTR, SHMT1, SHMT2, MTHFD2, SLC19A1 and FOLR1, all of which control folate uptake, reduction or one-carbon flux.
Why is tetrahydrofolate important for cell growth?
Tetrahydrofolate carries one-carbon units used for purine and thymidylate synthesis, so it is required for DNA replication and proliferation.
How is the cellular response to tetrahydrofolate studied?
It is studied with RNA-seq, metabolomics, isotope tracing, organoid culture, exosome profiling and CRISPR screens.
What diseases are linked to tetrahydrofolate response defects?
Antifolate chemotherapy toxicity, cerebral folate deficiency, pancreatic cancer and fibrosis are linked to altered tetrahydrofolate handling.
What is the role of methotrexate in this pathway?
Methotrexate inhibits DHFR and depletes tetrahydrofolate pools, and folinic acid or glucarpidase can rescue the resulting toxicity.
Can CRISPR knockout help study GO:1904482?
Yes, CRISPR knockout of DHFR, MTHFD2 or SLC19A1 can test whether a gene is required for the cellular response to tetrahydrofolate.
What is cerebral folate deficiency?
Cerebral folate deficiency is a neurological condition caused by insufficient folate availability in the central nervous system, demonstrating the importance of this response in the brain.
How does FOLFIRINOX relate to tetrahydrofolate?
FOLFIRINOX includes folinic acid and 5-fluorouracil, which perturb folate metabolism, and transcriptome-based classification can predict response.
What models are best for studying this response?
Patient-derived organoids, CRISPR knockout and knock-in cell lines, and overexpression models are widely used to study the response.
Conclusion
GO:1904482 cellular response to tetrahydrofolate is a compact ontology term for a broad and clinically important process. It connects tetrahydrofolate availability to nucleotide synthesis, one-carbon flux, methylation, secretion and immune remodeling, and it is directly relevant to antifolate chemotherapy, cerebral folate deficiency and fibrosis. Because the response is stimulus-driven and cell-state dependent, causal studies require precise genetic models. CRISPR knockout, point-mutation, knock-in and overexpression approaches, combined with transcriptomics, metabolomics and organoid systems, provide the experimental framework to dissect which genes truly mediate the response.
References
- 1. Xing R et al.. 2025. Enhanced formation of tertiary lymphoid structures shapes the anti-tumor microenvironment in hepatocellular carcinoma after FOLFOX-HAIC therapy.. Cell Rep Med 6(9):102298 PMID: 40818460
- 2. Lansbergen MF et al.. 2024. Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort.. Transl Res 273:137-147 PMID: 39154856
- 3. Chan BS et al.. 2025. Navigating methotrexate toxicity: Examining the therapeutic roles of folinic acid and glucarpidase.. Br J Clin Pharmacol 91(3):628-635 PMID: 38889902
- 4. Meliton AY et al.. 2025. Mitochondrial one-carbon metabolism is required for TGF-β-induced glycine synthesis and fibrotic responses.. Nat Commun 16(1):9250 PMID: 41115888
- 5. Gordon N. 2009. Cerebral folate deficiency.. Dev Med Child Neurol 51(3):180-2 PMID: 19260931
- 6. Zhu S et al.. 2025. SenExo-cCCT2 Reprograms Senescence Response and Anti-Tumor Immunity Following FOLFIRINOX Chemotherapy in Pancreatic Ductal Adenocarcinoma.. Adv Sci (Weinh) 12(38):e08431 PMID: 40686389
- 7. Kim JS et al.. 2025. Establishing 3D organoid models from patient-derived conditionally reprogrammed cells to bridge preclinical and clinical insights in pancreatic cancer.. Mol Cancer 24(1):162 PMID: 40462147
- 8. Lin EW et al.. 2026. Therapeutic Targeting of Epithelial-Mesenchymal Cellular Plasticity in Pancreatic Cancer.. Clin Cancer Res 32(5):869-882 PMID: 41364739
